|Articles|December 12, 2012

Social media as tool for obesity intervention

Facebook, Twitter, and other Internet-based technologies can be effective weapons in the fight against childhood obesity.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Meta-analysis finds vegetarian and vegan diets can support healthy growth in children

ByMorgan Ebert, Managing Editor

December 13th 2025

Edward Hook, MD, reacts to the FDA approval of zoliflodacin for uncomplicated urogenital gonorrhea

ByEdward Hook, MD

December 12th 2025

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

ByMorgan Ebert, Managing Editor

December 12th 2025

The benefits of gepotidacin for urogenital gonorrhea with Angela Hasler, APRN, CPNP-PC

By Angela Hasler, APRN, CPNP-PC

December 12th 2025

FDA approves powder formulation of trofinetide for Rett syndrome

ByMorgan Ebert, Managing Editor,Joshua Fitch, Senior Editor

December 12th 2025

Latest CME

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Social media as tool for obesity intervention

Newsletter

Related Content

Meta-analysis finds vegetarian and vegan diets can support healthy growth in children

Edward Hook, MD, reacts to the FDA approval of zoliflodacin for uncomplicated urogenital gonorrhea

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

The benefits of gepotidacin for urogenital gonorrhea with Angela Hasler, APRN, CPNP-PC

FDA approves powder formulation of trofinetide for Rett syndrome

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

Meta-analysis finds vegetarian and vegan diets can support healthy growth in children

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

Full case: A slender teen with a growing abdomen and shrinking height velocity

FDA approves gepotidacin as oral treatment for urogenital gonorrhea

Edward Hook, MD, reacts to the FDA approval of zoliflodacin for uncomplicated urogenital gonorrhea